Skip to main content
SpringerLink
Log in

Inhaled salmeterol/fluticasone propionate: a guide to its use in asthma

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs 2005; 65(12): 1715–34

    Article  PubMed  CAS  Google Scholar 

  2. Global Initiative for Asthma. GINA report: global strategy for asthma management and prevention (revised 2006) [online]. Available from URL: http://www.ginasthma.com [Accessed 2004 Dec 8]

  3. Glaxo Wellcome UK Limited. Seretide 100, 250, 500 Accuhaler: summary of product characteristics. Uxbridge, UK: Glaxo Wellcome UK Limited, 2006 Nov

    Google Scholar 

  4. Glaxo Wellcome UK Limited. Seretide 50, 125, 250 Evohaler: summary of product characteristics. Uxbridge, UK: Glaxo Wellcome UK Limited, 2006 Nov

    Google Scholar 

  5. GlaxoSmithKline. Advair Diskus 100/50, 250/50, 500/50 prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007 Feb

    Google Scholar 

  6. Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone propionate given as a combination: lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781–91

    Article  PubMed  CAS  Google Scholar 

  7. Bateman ED, Boushey HA, Bousquet J, et al. Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004 Oct; 170(8): 836–44

    Article  PubMed  Google Scholar 

  8. Strand AM, Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Danish INitiative for Asthma treatment. Respir Med 2004 Oct; 98(10): 1008–15

    Article  PubMed  Google Scholar 

  9. Nelson HS, Wolfe JD, Gross G, et al. Efficacy and safety of fluticasone propionate 44 (μg/salmeterol 21 μg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 2003 Sep; 91(3): 263–9

    Article  PubMed  CAS  Google Scholar 

  10. Murray J, Rosenthal R, Somerville L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting β2-agonists. Ann Allergy Asthma Immunol 2004 Oct; 93(4): 351–9

    Article  PubMed  CAS  Google Scholar 

  11. Bergmann K-C, Lindemann L, Braun R, et al. Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004 Jan 24; 134(3–4): 50–8

    PubMed  CAS  Google Scholar 

  12. Johansson G, McIvor RA, D’Ambrosio FP, et al. Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clin Drug Invest 2001; 21(9): 633–42

    Article  CAS  Google Scholar 

  13. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–34

    PubMed  CAS  Google Scholar 

  14. Busse W, Koenig SM, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily. J Allergy Clin Immunol 2003 Jan; 111(1): 57–65

    Article  PubMed  CAS  Google Scholar 

  15. Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94: 715–23

    Article  PubMed  CAS  Google Scholar 

  16. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1108–16

    Article  PubMed  CAS  Google Scholar 

  17. Pearlman DS, Peden D, Condemi JJ, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004; 41(8): 797–806

    Article  PubMed  CAS  Google Scholar 

  18. Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting β2-agonists alone. Am J Respir Crit Care Med 2001 Sep 1; 164: 759–63

    PubMed  CAS  Google Scholar 

  19. Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 2002 Feb; 88: 227–35

    Article  PubMed  CAS  Google Scholar 

  20. Weiler JM, Nathan RA, Rupp NT, et al. Effect of fluticasone/ salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Ann Allergy Asthma Immunol 2005 Jan; 94(1): 65–72

    Article  PubMed  CAS  Google Scholar 

  21. Aubier M, Pieters WR, Schlösser NJJ, et al. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876–84

    Article  PubMed  CAS  Google Scholar 

  22. Bateman ED, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16(3): 193–201

    Article  CAS  Google Scholar 

  23. Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999 Jan–Feb 28; 6(1): 45–51

    PubMed  CAS  Google Scholar 

  24. Fitzgerald JM, Boulet L-P, Follows RMA. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005 Apr; 27(4): 393–406

    Article  PubMed  CAS  Google Scholar 

  25. Dahl R, Chuchalin A, Gor D, et al. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/ budesonide combinations in adults with persistent asthma. Respir Med 2006 Jul; 100(7): 1152–62

    Article  PubMed  Google Scholar 

  26. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/ salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000 Dec; 106(6): 1088–95

    Article  PubMed  CAS  Google Scholar 

  27. Ringdal N, Eliraz A, Pruzinec P, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003 Mar; 97: 234–41

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inhaled salmeterol/fluticasone propionate: a guide to its use in asthma. Drugs Ther. Perspect 23, 1–4 (2007). https://doi.org/10.2165/00042310-200723110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200723110-00001

Search

Navigation